Cargando…
Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data
Hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+/HER2 negative) breast cancer accounts for over 70% of all breast cancers. There has been much advancement in the treatment of HR+/HER2 negative metastatic breast cancer (MBC), in particular the development of more tail...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680678/ https://www.ncbi.nlm.nih.gov/pubmed/33239910 http://dx.doi.org/10.2147/BCTT.S219436 |